Skip to content

Novavax: Now Or Never?

2020-07-15 10_27_56-WindowAfter being awarded $1.6 billion in funding by the U.S. government as part of its fast-track COVID-19 vaccine program Operation Warp Speed – the largest deal made by the program – shares of Novavax surged 32% in one trading session. On the heels of this surge, do shares of Novavax have more room to run – or is there little potential left in this biotech that has yet to turn a profit or successfully bring a product to market? For why the author of today’s article believes that Novavax stock is a buy – but only for aggressive investors with an appetite for risk – CLICK HERE.